Altimmune Announces Patient Enrollment Begins In PERFORMA Phase 3 Trial Of Pemvidutide In MASH, Enrolling About 1,790 Patients Across Two Cohorts, 52-Week Data Expected In 2029
Share
Why It Matters
Altimmune started testing a new medicine called pemvidutide to help people with a serious liver disease. This is an important step forward, but we won't know if it actually works until 2029.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.